Prescient Therapeutics Limited
ASX:PTX.AX
Overview | Financials
Company Name | Prescient Therapeutics Limited |
Symbol | PTX.AX |
Currency | AUD |
Price | 0.041 |
Market Cap | 33,018,120 |
Dividend Yield | 0% |
52-week-range | 0.037 - 0.105 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Steven Lee Yatomi-Clarke |
Website | https://ptxtherapeutics.com |
An error occurred while fetching data.
About Prescient Therapeutics Limited
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD